Printer Friendly

Vardenafil found superior for improving premature ejaculation.

SAN ANTONIO -- Vardenafil improved premature ejaculation more than sertraline, Frank Sommer, M.D., reported at the annual meeting of the American Urological Association.

Both vardenafil (Levitra), a phosphodiesterase-5 inhibitor, and sertraline (Zoloft), a selective serotonin reuptake inhibitor, resulted in significant improvements in several measures of premature ejaculation (PE) over baseline, but vardenafil proved significantly better than sertraline on all measures.

The relatively small, crossover study involved 34 heterosexual men who reported PE more than half the time and who had intravaginal ejaculatory latency times (IVELT) of less than 1.5 minutes at baseline. PE was the primary complaint in 8 (24%) of the men and was secondary (in most cases to erectile dysfunction) in the remaining 26 men (77%).

After a 4-week run-in period, 17 men were given 10-mg vardenafil 10 minutes before intercourse for 6 weeks. The other 17 received 50 mg of sertraline 4 hours before intercourse. After a 1-week washout period, the men who had been receiving sertraline switched to vardenafil and vice versa for an additional 6 weeks.

On a self-rating scale of 0-8, where 0 means PE almost never, 4 means PE about half the time, and 8 means PE almost always, the mean score was 6.14 at baseline, 4.28 with sertraline, and 3.2 with vardenafil.

IVELT, as measured by a stopwatch, averaged 0.54 minutes at baseline, 2.87 minutes with sertraline, and 5.23 minutes with vardenafil, reported Dr. Sommer, who conducted the research at the Cologne (Germany) University Medical Center but is now at the University of Hamburg.

Self-ratings of sexual satisfaction, on a 0-5 scale, where 0 means not at all satisfied and 5 means extremely satisfied, averaged 1.4 at baseline, 3.2 with sertraline, and 4.2 with vardenafil. In addition, the partners' sexual satisfaction showed significant increases for sertraline and even more so for vardenafil.

Dr. Sommer stated that he had no conflicts of interest related to his study.


San Francisco Bureau
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:care and treatment
Author:Finn, Robert
Publication:Clinical Psychiatry News
Geographic Code:1USA
Date:Nov 1, 2005
Previous Article:Treatment-resistant OCD.
Next Article:TV watching, parental support predict bullying.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |